Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08).
Roger Von Moos
Consultant or Advisory Role - Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; Merck Serono; Merck Sharp & Dohme; MSD; Novartis; Novartis; Pfizer; Roche; Roche
Honoraria - Amgen; Amgen; Roche; Roche
Research Funding - Amgen; Amgen; Roche; Roche
Expert Testimony - Amgen (U); Amgen (U)
Dieter Koeberle
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose
Richard Cathomas
No relevant relationships to disclose
Roman Ignaz Inauen
No relevant relationships to disclose
Daniel Rudolf Zwahlen
No relevant relationships to disclose
Arnaud Roth
No relevant relationships to disclose
Daniel Helbling
No relevant relationships to disclose
Oliver Gautschi
No relevant relationships to disclose
Daniela Baertschi
No relevant relationships to disclose
Reto Kuehne
No relevant relationships to disclose
Thomas Von Briel
No relevant relationships to disclose
Anja Grzesiczek
No relevant relationships to disclose
Panagiotis Samaras
Consultant or Advisory Role - Bayer
Honoraria - Bayer; Roche
Attila Kollar
No relevant relationships to disclose
Dirk Klingbiel
No relevant relationships to disclose
Kathrin Zaugg
No relevant relationships to disclose